Patients with polycystic ovary syndrome (PCOS) can suffer from psychological disorders, among which depression is the most commonly diagnosed. However, the pathogenesis is still unclear. The aims of the present study were to investigate the behaviors of dehydroepiandrosterone (DHEA)-induced PCOS mice, the effects of high-fat diet (HFD) on mouse behaviors, and the underlying mechanism. Prepubertal C57BL/6 mice (25 days of age) were divided into four groups and injected daily with the vehicle sesame oil or DHEA on the normal chow or a 60% HFD for 20 consecutive days. Depression-like behavior of the mice was examined using a forced swim test, tail suspension test, and open field test. Thereafter, the animals were killed and four brain regions were collected. The brain levels of monoamines and their metabolites, including norepinephrine, serotonin, 5-hydroxy-3-indolacetic acid, dopamine, and 3,4-hydroxyphenylacetic acid, were analyzed by HPLC. Our data show that DHEAtreated mice exhibited depression-like behavior according to the results from behavioral assessment. The brain contents of monoamines and/or their metabolites decreased in DHEAtreated mice compared with controls. HFD did not seem to markedly affect the behavioral responses, the brain monoamines, or their metabolites in the mice. These findings suggest that DHEA treatment induced depression-like behavior in PCOS mice, possibly through down-regulation of brain monoamines and/or their metabolites, which implies the contribution of hyperandrogenism to the psychological symptoms of women with PCOS.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-aged women. About 12%-18% of women suffer from PCOS with the characteristics of hirsutism, acne, menstrual irregularities, hyperandrogenemia, polycystic ovaries, obesity, infertility, and so on [1, 2] . In addition to reproductive and metabolic disorders, women with PCOS may also suffer from psychological distress [3, 4] . Clinical studies have shown that approximately 56.9% of women with PCOS have at least one psychiatric disorder, such as depressed mood, loss of activity, intensified fatigue, poor concentration, sleep disturbance, and suicide attempts [5] . Among all kinds of mood disturbances, depression is the most commonly diagnosed [6] . Women with PCOS are reported to experience depressive episodes about three times more frequently than healthy controls [7, 8] . Clinical efforts have focused on revealing the etiology of depression in PCOS. However, the current results are controversial, and the causes of depression in women with PCOS still remain unknown [9, 10] .
Despite being the most prevalent form of psychiatric disability, the pathophysiology of depression is poorly understood. Several hypotheses have been proposed, among which the monoamine hypothesis is the most widely recognized. Based on this hypothesis, monoamine imbalance, particularly neurotransmitter (e.g., serotonin , norepinephrine [NE] , and dopamine [DA] ) deficiency in certain brain areas, causes depression [11] . However, limited data are available pertaining to the central monoamine levels in association with depression in PCOS patients or animal models.
Recently, Ressler et al. have shown the depression-and anxiety-like behaviors in a PCOS rat model induced by dihydrotestosterone (DHT) [12] . In addition, they also demonstrated that high-fat diet (HFD) consumption exacerbated depressive behaviors in these rats. Treatment of the animals with dehydroepiandrosterone (DHEA) is another well-established and widely used means to generate PCOS animal models. We have previously reported that HFD causes significant metabolic disorders in DHEA-induced PCOS mice [13] . Whether DHEA-induced PCOS animals exhibit the depression-like behaviors is unknown. Therefore, the aims of the present study were to investigate the behaviors of DHEAinduced PCOS mice, the effect of HFD in this context, and the mouse brain levels of monoamines and their metabolites.
MATERIALS AND METHODS

Animals and Treatments
Female C57BL/6 mice (age 21 days) were purchased from the animal facility of Peking University Health Science Center. All animals were bred, housed locally at 22 6 28C, and acclimated to standard laboratory conditions (12L:12D cycle) with free access to rodent food and water. At Postnatal Day 25, mice of comparable weights were randomly divided into four groups (n ¼ 7/ group): group 1, control group (oil-normal chow)-mice were fed with normal chow and injected subcutaneously (s.c.) daily with sesame oil (0.1 ml/100 g body weight); group 2, DHEA group (DHEA-normal chow)-mice were fed with normal chow and injected (s.c.) daily with DHEA (6 mg/100 g body weight) dissolved in 0.1 ml of sesame oil; group 3, HFD group (oil-HFD)-mice were fed an HFD (60% of calories from fat; Research Diets, New Brunswick, NJ) and injected (s.c.) daily with sesame oil (0.1 ml/100 g body weight); group 4, DHEA þ HFD group (DHEA-HFD)-mice were fed an HFD and injected (s.c.) daily with DHEA. After the treatments for 20 days, behavioral tests were performed. The treatments were continued until the mice were killed. All experimental protocols were approved by the Ethics Committee for Animal Experimentation of the Faculty of Medicine of Peking University Health Science Center in accordance with guidelines from the U.S. National Institutes of Health. DHEA and sesame oil were purchased from Sigma-Aldrich (St. Louis, MO). Additional information about the animal model used in the study can be found in our previous work [13] .
Behavioral Assessment
The behaviors of the mice were assessed by forced swim test (FST), tail suspension test (TST) , and open field test (OFT). The tests were carried out in the order of FST, TST, and OFT with an interval of at least 24 h between the tests for each animal. All the tests were performed during the light period of the light-dark cycle under quiet conditions and were recorded by a video camera. The tests were evaluated by three experienced persons who independently scored the videos blindly. Averages of the three scores were determined as the final scores.
Forced Swim Test
The FST was performed as described previously [14, 15] . In brief, each animal was placed in a cylinder (height, 40 cm; diameter, 20 cm) filled with water (25 6 18C) to a depth of 15 cm. All the mice were forced to swim for 15 min (pretest), followed by a formal 5-min test 24 h later. Immobile time was determined by the time when a mouse ceased struggling and remained floating motionless in the water, making only small movements to keep its head above water. The duration of immobility was recorded during the 5-min testing period.
Tail Suspension Test
The TST was carried out as described previously [16, 17] . In brief, each mouse was suspended 50 cm above the table by adhesive tape, fixed approximately 1 cm from the tip of the tail. Immobility time was determined by the time when a mouse remained completely motionless. The duration of the test was 6 min.
Open Field Test
The OFT was performed as described previously [18, 19] . In brief, each mouse was placed in the left corner of a white open chamber (60 3 60 3 60 cm 3 ) equipped with a videotape. All the locomotion was recorded by the camera for 10 min. The chamber was cleaned thoroughly with 75% ethanol and dried with paper towels between two individual tests. The total distance traveled was analyzed by a real-time color image video-tracking system SMART ver.2.5.21 (Panlab Harvard Apparatus, Panlab, Spain).
Tissue Collection
Mice were housed for 3 days after the behavioral tests and were then deeply anesthetized via an intraperitoneal injection of a mixture of ketamine hydrochloride and xylazine. The brains were isolated on an ice bath. Four brain regions, including hippocampus, striatum, hypothalamus, and dorsal raphe nucleus (DRN), were rapidly separated, weighed, and snap frozen in liquid nitrogen, and then kept at À808C for monoamine measurement.
Measurement of Brain Monoamines and Their Metabolites
Brain tissues were ultrasonically homogenized in the ice-cold HClO4 solution (0.2 M) containing 0.05 M EDTA-2Na. The mixtures were then centrifuged twice at 18 000 3 g at 48C for 40 min. Supernatants were collected for analysis of monoamines and their metabolites using HPLC with electrochemical detection (Dionex UltiMate 3000; Thermo Scientific, Santa Clara, CA) and a C18 reverse-phase column (3.0 mm inside diameter 3 75 mm, Capcell Pak C18 MG S3; Shiseido, Japan). The mobile phase contained 0.1 M NaH 2 PO4, 0.85 mM 1-octanesulfonic acid, 0.5 mM EDTA-2Na, and 11% methanol. The pH of the solution was adjusted to 3.25 using phosphoric acid. The concentrations of the monoamines and their metabolites in the samples were calculated and expressed as micrograms per gram tissue.
Statistical Analysis
The values were presented as mean 6 SEM. Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, Inc.). Effects of the treatments were analyzed by two-way ANOVA followed by Bonferroni multiple comparisons test with HFD and DHEA as the independent factors to assess the possible interactions between them. P , 0.05 was considered statistically significant.
RESULTS
Effects of the Treatments on the Mice in FST
The FST is widely used to screen antidepressants. Duration of immobility measured in the FST is used as an index of depression-like behavior. Data from two-way ANOVA showed that HFD and DHEA had significant effects on immobile time in FST, but there was no significant interaction between them (interaction, F (1, 17) ¼ 0.2292; P ¼ 0.6382). The immobile time was significantly higher in the HFD and DHEA mice than in controls (P , 0.01 and P , 0.05, respectively). Meanwhile, the DHEA þ HFD mice showed a significant increase in duration of immobility compared with the mice treated with HFD or DHEA alone (P , 0.05 and P , 0.05, respectively; Fig. 1A ). These data suggest that treatment with HFD, DHEA, or the combination of DHEA and HFD induced depression-like behavior in the mice.
Effects of the Treatments on the Mice in TST
Similar to the FST, the immobile time in TST is commonly used to assess depression in mice. Data from two-way ANOVA showed that the treatment of DHEA, rather than HFD, had significant effects on immobile time in TST. There was no significant interaction between DHEA and HFD (interaction, F (1, 21) ¼ 0.3252; P ¼ 0.5745). No statistical difference was found between control and HFD mice (Fig. 1B) . DHEA and DHEA þ HFD animals exhibited a significant increase in immobile time compared with control and HFD mice, respectively (P , 0.05 and P , 0.05, respectively). These results suggest that DHEA, rather than HFD, induced depression-like behavior in the animals.
Effects of the Treatments on the Mice in OFT
The OFT is designed to measure locomotor activity and exploratory behavior in the mice. The total distance traveled is a reflection of depression-like behavior [20] . Data from two-way ANOVA showed that the treatment of DHEA, rather than HFD, had significant effects on total distance in OFT. There was no significant interaction between DHEA and HFD (interaction, F (1, 20) ¼ 0.0115; P ¼ 0.9157). No marked difference was found between control and HFD mice (Fig. 1C) . The total distance was significantly decreased in DHEA and DHEA þ HFD mice compared with control and HFD mice, respectively (P , 0.01 and P , 0.01, respectively). Moreover, no apparent difference was found between DHEA and DHEA þ HFD mice. These data imply a depressive tendency in DHEA-treated mice, irrespective of the diet. HFD consumption did not affect the behavior of the mice.
Levels of Monoamines and Their Metabolites in the Hippocampus
To investigate the possible mechanism underlying the depression-like behavior in the DHEA-induced PCOS mice, we measured the brain levels of NE, 5-HT, 5-hydroxy-3-indolacetic acid (5-HIAA), DA, and 3,4-hydroxyphenylacetic acid (DOPAC) in the animals. In the hippocampus, treatment YU ET AL.
of DHEA, rather than HFD, had significant effects on NE levels, and there was no significant interaction between DHEA and HFD treatments (interaction, F (1, 22) ¼ 0.039; P ¼ 0.8453), as analyzed by two-way ANOVA. No difference in NE levels was found between control and HFD mice ( Fig. 2A) . The hippocampal NE contents in the DHEA and DHEA þ HFD mice were significantly lower than those in control and HFD mice, respectively (P , 0.01 and P , 0.01, respectively).
Similar to NE, there was no difference in 5-HIAA, the metabolite of 5-HT, between control and HFD animals (Fig. 2B) . Treatment with DHEA, rather than HFD, had significant effects on 5-HIAA levels, and there was no significant interaction between DHEA and HFD (interaction, F (1, 24) ¼ 0.0779; P ¼ 0.7826). 5-HIAA contents were significantly decreased in DHEA and DHEA þ HFD mice compared with control and HFD mice, respectively (P , 0.01 and P , 0.01, respectively). 5-HT was too low to be detected in the mouse hippocampus.
Levels of DA and its metabolite DOPAC were also measured. Likewise, there was no difference in DA between control and HFD animals (Fig. 2C) . Treatment with DHEA, but not HFD, had significant effects on DA levels. There was no significant interaction between DHEA and HFD (interaction, F (1, 20) ¼ 0.1986; P ¼ 0.6606). There was no marked difference between DHEA and control, or between DHEA þ HFD and HFD mice. No statistical difference was found in the hippocampal DOPAC levels among the four groups of mice (Fig. 2D) .
Taken together, these data suggest that DHEA treatment reduced the mouse hippocampal monoamine and/or metabolite contents, especially NE and 5-HIAA. HFD did not show any apparent effect on the hippocampal levels of monoamines or their metabolites.
Levels of Monoamines and Their Metabolites in the Striatum
DA is one of the major neurotransmitters associated with depression, and the striatum is a main site of DA projection. Data from two-way ANOVA revealed the significant effects of DHEA, but not HFD, on striatal NE, 5-HIAA, DA, and DOPAC levels, and there was no significant interaction between DHEA and HFD (interaction, F (1, 19) ¼ 0.6569, P ¼ 0.4277; F (1, 19) ¼ 0.1791, P ¼ 0.6769; F (1,17) ¼ 3.07, P ¼ 0.0978; and F (1, 16) ¼ 0.2282, P ¼ 0.6393, respectively). There was no difference in the striatal NE, 5-HIAA, DA, or DOPAC levels between control and HFD mice (Fig. 3, A-D) . Treatment of the mice with DHEA or DHEA þ HFD led to a significant decrease in 5-HIAA, DA, and DOPAC levels compared with control and HFD mice, respectively (P , 0.01 and P , 0.01, respectively; Fig. 3, B-D) . Levels of 5-HT were undetectable in the striatum. These data confirmed that DHEA treatment led to the down-regulation of monoamines and their metabolites in the striatum, especially 5-HIAA, DA, and DOPAC. HFD did not show any apparent effect on the striatal levels of monoamines or their metabolites. 2 . Effects of the treatments on the levels of monoamines and their metabolites in the hippocampus of the mice. A) NE levels. B) 5-HIAA levels. C) DA levels. D) DOPAC levels. Data are presented as mean 6 SEM. Global P , 0.0001 and P ¼ 0.7532 for the treatments with DHEA and HFD in the NE levels, respectively; P , 0.0001 and P ¼ 0.9627 for the treatments with DHEA and HFD in the 5-HIAA levels, respectively; P ¼ 0.0114 and P ¼ 0.5917 for the treatments with DHEA and HFD in the DA levels, respectively; P ¼ 0.0998 and P ¼ 0.7975 for the treatments with DHEA and HFD in the DOPAC levels, respectively. **P , 0.01 versus control (oil-normal chow) or HFD (oil-HFD). n ¼ 7/group.
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Levels of Monoamines and Their Metabolites in the Hypothalamus
Data from two-way ANOVA revealed the significant effects of DHEA, but not HFD, on hypothalamic NE, 5-HIAA, DA, and DOPAC levels, and there was no significant interaction between DHEA and HFD (interaction, F (1, 19) 3 . Effects of the treatments on the levels of monoamines and their metabolites in the striatum of the mice. A) NE levels. B) 5-HIAA levels. C) DA levels. D) DOPAC levels. Data are presented as mean 6 SEM. Global P ¼ 0.037 and P ¼ 0.0919 for the treatments with DHEA and HFD in the NE levels, respectively; P , 0.0001 and P ¼ 0.8226 for the treatments with DHEA and HFD in the 5-HIAA levels, respectively; P , 0.0001 and P ¼ 0.4787 for the treatments with DHEA and HFD in the DA levels, respectively; P , 0.0001 and P ¼ 0.1117 for the treatments with DHEA and HFD in the DOPAC levels, respectively. **P , 0.01 versus control (oil-normal chow) or HFD (oil-HFD). n ¼ 7/group.
DEPRESSION IN DHEA-INDUCED PCOS MICE
was no difference in the levels of the three monoamines or their metabolites between control and HFD mice (Fig. 4, A-D) . The hypothalamic contents of NE, 5-HIAA, DA, and DOPAC were significantly lower in DHEA animals than in controls (P , 0.01; Fig. 4, A-D) . In addition, NE and DA contents were significantly lower in DHEA þ HFD mice than in HFD mice (P , 0.01; Fig. 4, A and C) . The hypothalamic 5-HT contents were too low to be detected. These results imply that DHEAinduced mice presented lower monoamine and/or their metabolite contents in the hypothalamus. Moreover, HFD did not affect the hypothalamic levels of monoamines or their metabolites.
FIG. 4.
Effects of the treatments on the levels of monoamines and their metabolites in the hypothalamus of the mice. A) NE levels. B) 5-HIAA levels. C) DA levels. D) DOPAC levels. Data are presented as mean 6 SEM. Global P , 0.0001 and P ¼ 0.8989 for the treatments with DHEA and HFD in the NE levels, respectively; P ¼ 0.0045 and P ¼ 0.6012 for the treatments with DHEA and HFD in the 5-HIAA levels, respectively; P , 0.0001 and P ¼ 0.5287 for the treatments with DHEA and HFD in the DA levels, respectively; P ¼ 0.0053 and P ¼ 0.3511 for the treatments with DHEA and HFD in the DOPAC levels, respectively. **P , 0.01 versus control (oil-normal chow) or HFD (oil-HFD). n ¼ 7/group.
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FIG. 5. Effects of the treatments on the levels of monoamines and their metabolites in the DRN of the mice. A) NE levels. B) 5-HT levels. C) 5-HIAA levels. D) DA levels. E) DOPAC levels. Data are presented as mean 6 SEM. Global P ¼ 0.0132 and P ¼ 0.0594 for the treatments with DHEA and HFD in the NE levels, respectively; P ¼ 0.0006 and P ¼ 0.4862 for the treatments with DHEA and HFD in the 5-HT levels, respectively; P ¼ 0.7387 and P ¼ 0.7006 for the treatments with DHEA and HFD in the 5-HIAA levels, respectively; P ¼ 0.5035 and P ¼ 0.1758 for the treatments with DHEA and HFD in the DA levels, respectively; P ¼ 0.1351 and P ¼ 0.4276 for the treatments with DHEA and HFD in the DOPAC levels, respectively. *P , 0.05, **P , 0.01 versus control (oil-normal chow) or HFD (oil-HFD); ## P , 0.01, HFD versus control. n ¼ 7/group.
DEPRESSION IN DHEA-INDUCED PCOS MICE
Levels of Monoamines and Their Metabolites in the DRN
The DRN contains the most abundant 5-HT neurons [21] . As showed in Figure 5A , the NE contents in the DRN were significantly lower in HFD and DHEA mice than in controls (P , 0.01 and P , 0.01, respectively). Data from two-way ANOVA showed the significant effects of DHEA, but not HFD, on NE levels in the DRN, and there was significant interaction between DHEA and HFD (interaction, F (1,13) ¼ 10.25; P ¼ 0.0069). The 5-HT and 5-HIAA were also detected in the DRN (Fig. 5, B and C) . There was no difference in 5-HT levels between control and HFD mice. The 5-HT content in the DNR of DHEA and DHEA þ HFD mice was significantly lower than in control and HFD mice (P , 0.01 and P , 0.05, respectively). Data from two-way ANOVA revealed the significant effects of DHEA, but not HFD, on 5-HT levels, and there was no significant interaction between DHEA and HFD (interaction, F (1, 12) ¼ 0.4880; P ¼ 0.4981). There was no marked difference in 5-HIAA, DA, or DOPAC content among the four groups of mice (Fig. 5, C-E) . In addition, there was no significant effect or interaction between DHEA and HFD on 5-HIAA, DA, or DOPAC levels (interaction, F (1, 14) ¼ 0.0001, P ¼ 0.9912; F (1,13) ¼ 0.0945, P ¼ 0.7634; and F (1, 13) ¼ 0.0770, P ¼ 0.7858, respectively). These data suggest that DHEA reduced DRN monoamine and/or their metabolite contents, especially 5-HT and NE. With the exception of NE contents, HFD did not show any apparent effects on the DRN levels of monoamines or their metabolites in the mice.
DISCUSSION
A growing body of evidence has suggested an increased risk of depression disorders in women with PCOS [7, 8, 22] . Hollinrake et al. have shown the high prevalence of depression in PCOS patients (35%) compared with control subjects (10.7%) [23] . The study by Kerchner et al. indicated the incidence of depression at a high rate of 40%-60% in women with PCOS [24] . Women with depression have poor social adjustment and poor quality of life [25] . In spite of the high incidence of depression and its negative impact on the quality of life, the causes of depression in women with PCOS are unclear.
Clinical studies have investigated the potential link between obesity, insulin resistance (IR), androgens, and so on with depression. However, there is much debate concerning the relationship between obesity and depression in PCOS. Hollinrake et al. have reported that depressed PCOS subjects had a higher body mass index (BMI) and evidence of IR than nondepressed PCOS subjects [23] . In some studies, clear correlations were also found between BMI and depression [26, 27] . In contrast, other research did not detect any significant difference in BMI between depressed and nondepressed PCOS women [22, 28] . A meta-analysis performed by Dokras et al. reported that the high risk of depressive symptoms was independent of BMI in women with PCOS [6] . In animal studies, Ressler et al. have found depression-like behaviors in a DHT-induced PCOS rat model. In addition, consumption of a 40% HFD for 12 wk induced obesity and increased immobility during the FST in both DHT and control rats, especially in DHT-treated animals [12] . We have previously shown that a 60% HFD caused obesity in DHEA-induced PCOS mice. In the present study, we demonstrated the depression-like behavior in both DHEA-and DHEA þ HFD-treated mice, as manifested by longer duration of immobility during FST and TST, less total distance during OFT, and the decreased levels of brain monoamines and/or their metabolites. HFD seemed to cause depression-like behavior in the mice, as evidenced by the results from FST. However, results from TST and OFT suggested that the behavioral phenotype of the HFD mice was similar to that of controls. Likewise, the behavioral phenotype of the DHEA mice was also similar to that of the DHEA þ HFD mice. The further measurement of the brain monoamines and their metabolites did not show any significant difference between control and HFD mice, or between DHEA and DHEA þ HFD mice, except the NE levels in the DRN. Taken together, a 60% HFD did not appear to markedly affect the behaviors or brain monoamine levels in either control or DHEA animals in this context. In addition, it seems to be more reasonable to evaluate the behavioral phenotype of the mice by more than one test. Several factors may account for the discrepancies between results from Ressler et al. and ours. One possibility is the different PCOS animal models that were applied. In our study, DHEA was administered for 3 wk to induce the PCOS mouse model. In contrast, DHT pellets were implanted for 3 mo to generate the DHT-induced PCOS rat model. In addition, a 60% HFD was consumed for 3 wk in the present study, and a 40% HFD was consumed for 12 wk in the study by Ressel et al. We have previously shown that HFD caused significant metabolic alterations in DHEA-treated mice, including obesity, glucose intolerance, dyslipidemia, etc. [29] . How HFD consumption affects depression is still controversial. Finger et al. have shown the protective role for a 45% HFD in stress-induced depression-like behavior [30] . Conversely, adult male C57BL6 mice on a 58% HFD for 12 wk showed depression-like behavior [31] . It is likely that the percentage of the fat in the diet and the feeding period may differentially impact the behaviors of the animals.
Hyperandrogenism is a key feature of PCOS. It is still controversial whether hyperandrogenism is associated with depression in women with PCOS. Some studies have found higher serum androgen levels in depressed than in nondepressed PCOS patients [5, 32] . However, others have reported that there was an association between lower circulating concentrations of free testosterone and worse self-reported depression symptoms in women with PCOS [33] , or there were no significant differences in total or free testosterone levels, or in the adrenal androgen DHEAS between depressed and nondepressed women with PCOS [23] . Differently, Weiner et al. have reported that women with PCOS were mostly depressed when free testosterone levels were just outside the normal range [34] . Depression decreased when free testosterone levels were above or below this range. The results from animal studies seemed to be different. Data from Ressler et al. and our laboratory have demonstrated the apparent relationship between depression and hyperandrogenism in DHT-and DHEA-induced animal models of PCOS, respectively. Feng et al. have reported androgen-induced anxiety-related behavior in female rats [35] . Very recently, they have also shown that maternal testosterone exposure increases anxiety-like behavior in the offspring [36] . It seems likely that androgen-induced animal models of PCOS exhibit mood disturbances, and can thus serve as the experimental tools for future fundamental research into the mechanisms underlying depression and anxiety in women with PCOS.
Over the years, the monoamine theory has been the prevailing hypothesis of depression. It was brought forward in the 1960s [37] , and states the association between reduced monoamine function and depression. Previous studies have linked the brain monoamine alterations to the depressive behaviors assessed by FST, TST, and OFT [38, 39] . Increased immobility time and reduced locomotive activities were associated with reduced monoamine activity in the brain. In YU ET AL.
PCOS patients or animal models, however, it is unknown whether the brain monoamine levels vary with depressive behaviors. Shi et al. have reported that the depressive and anxious subscales were significantly higher and serum concentrations of 5-HT, 5-HIAA, and DA metabolite, homovanillic acid, were significantly lower in infertile women with PCOS than those without PCOS [40] , implying a link between depression disorders and changed neurotransmitter contents in PCOS patients. Currently, no information is available regarding the brain monoamine levels in animal models of PCOS. To further understand the neurological processes that may contribute to the depression-like behavior in the DHEA-induced PCOS mice, we measured the mouse brain contents of monoamines and their metabolites.
Levels of NE, DA, 5-HT, and their metabolites were determined in four different brain regions. The hippocampus, a brain region that regulates memory and learning processes, is also involved in depression and is an important target for antidepressants [41] [42] [43] . The striatum is a brain area where the dopaminergic neurons in the substantia nigra project to maintain DA homeostasis [44] . Deficiency of dopaminergic function in the striatum could be involved in the potential mechanism of depression, and the low DA levels in the striatum may result in depression [45, 46] . The hypothalamus was also chosen because developmental abnormalities of the hypothalamus are associated with alterations in body growth and sexual development, leading to adverse physiological and neurological conditions, such as depression, chronic stress, and obesity [47] . The DRN contains the most abundant 5-HT neurons. It is strongly associated with brain dysfunction, especially mood disorders, such as depression [21] . In the present study, the decreased levels of two or more monoamines and/or their metabolites were found in the hippocampus, striatum, hypothalamus, and/or DRN of the mice treated with DHEA or DHEA þ HFD. HFD did not significantly affect these monoamine neuromodulator levels in most of these brain regions. The results from brain monoamine and/or their metabolite measurement were consistent with the data from the behavioral tests, suggesting the involvement of monoaminergic modulation in the mechanism underlying depression-like behavior in DHEAinduced PCOS mice.
In summary, we have demonstrated that DHEA-induced PCOS mice exhibited depression-like behavior, possibly via modulation of the brain monoamine and/or their metabolite levels. Consumption of a 60% HFD did not have marked effects on either the behaviors or brain monoamine levels in the control or DHEA-treated mice. Our data imply the contribution of hyperandrogenism to the psychological symptoms of women with PCOS. In the future, androgen-induced animal models of PCOS are expected to provide more valuable information for the better understanding of the pathophysiology of depression in PCOS patients.
